)
Lineage Cell Therapeutics (LCTX) investor relations material
Lineage Cell Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Advanced OpRegen program with eight new clinical sites and durable 36-month efficacy, supported by Roche/Genentech and RMAT designation.
Strategic partnership with William Demant Invest secured up to $12 million for Resonance (ANP1) hearing loss program, validating the platform and funding preclinical milestones.
Initiated large-scale manufacturing for iLET Cell (Type 1 Diabetes), with early work suggesting scalable islet cell production and a go/no-go decision expected next quarter.
OPC-1 program dosed first patient in DOSED study for spinal cord injury, with no significant safety events and CIRM grant finalist status for up to $7 million in non-dilutive funding.
Business model leverages internal development and strategic partnerships, focusing on scalable pluripotent cell platform and value creation.
Financial highlights
Q3 2025 revenues were $3.7 million, down $0.1 million year-over-year; nine-month revenue was $7.9 million, up 20% year-over-year.
Operating expenses for Q3 2025 were $7.5 million, with R&D at $3.3 million and G&A at $4.2 million.
Net loss for Q3 2025 was $29.8 million ($0.13/share), mainly due to a $26.6 million non-cash warrant liability remeasurement; nine-month net loss was $64.4 million.
Cash, cash equivalents, and marketable securities totaled $40.5 million as of September 30, 2025, expected to fund operations into Q2 2027.
Recorded a $14.8 million non-cash impairment charge for abandonment of the VAC platform.
Outlook and guidance
Cash runway extends into Q2 2027, not including potential milestone payments from Roche/Genentech or CIRM grant funds.
Expects continued momentum in 2026, driven by OpRegen progress, expanded partnerships, and manufacturing innovations.
Up to $36 million in potential proceeds from warrant exercises and $38.7 million available under the ATM program.
Awaiting CIRM grant decision, which could offset up to 50% of OPC-1 trial costs and free up capital for other programs.
Ongoing pursuit of additional capital through equity, grants, and collaborations.
Next Lineage Cell Therapeutics earnings date
Next Lineage Cell Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage